VEGFA and neoplasm: Additionally, Ullrich and co-workers elucidated that, in a mouse model of small cell lung cancer (SCLC), anti-VEGF in combination with anti-PD-L1 synergistically enhanced the therapeutic outcomes in terms of the tumor progression compared with anti-PD-L1 or anti-VEGF monotherapy.